TherapeuticsMD, Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

TXMD$1.74+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except per share data)

	September 30, 2025	December 31, 2024
(Unaudited)
Assets:
Current assets:
Cash and cash equivalents	$7,115	$5,059
Royalty receivable, current portion	3,665	3,562
Prepaid and other current assets	3,723	3,638
Total current assets	14,503	12,259
License rights and other intangible assets, net	3,914	4,321
Right of use assets	5,515	6,102
Royalty receivable, long term	14,269	16,010
Other non-current assets	470	130
Total assets	$38,671	$38,822
Liabilities and stockholders’ equity:
Current liabilities:
Accounts payable	$263	$258
Accrued expenses and other current liabilities	2,015	2,127
Current liabilities of discontinued operations	2,667	2,781
Total current liabilities	4,945	5,166
Operating lease liabilities	5,411	5,542
Other non-current liabilities	871	744
Total liabilities	11,227	11,452
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, par value $0.001; 32,000 shares authorized, 11,574 and 11,532 issued and outstanding as of September 30, 2025 and December 31, 2024	11	11
Additional paid-in capital	979,205	979,181
Accumulated deficit	(951,772)	(951,822)
Total stockholders’ equity	27,444	27,370
Total liabilities and stockholders’ equity	$38,671	$38,822

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.